Bridging therapy during delayed definitive radiotherapy in locally advanced head and neck squamous cell carcinoma: a prospective randomized study comparing induction TPF chemotherapy with oral metronomic chemotherapy
DOI:
https://doi.org/10.18203/2320-6012.ijrms20263111Keywords:
Bridging therapy, Head and neck squamous cell carcinoma, Induction chemotherapy, Oral metronomic chemotherapyAbstract
Background: Prolonged waiting periods before definitive radiotherapy remain a major challenge in the management of locally advanced head and neck squamous cell carcinoma (LA-HNSCC), particularly in resource-constrained healthcare settings. Bridging systemic therapy during this interval may help maintain disease control until definitive radiotherapy can be initiated. The aim of the study was to compare the efficacy and safety of induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy with oral metronomic chemotherapy (OMCT) as bridging treatment in patients with LA-HNSCC experiencing unavoidable delays before definitive radiotherapy.
Methods: A prospective randomized study was conducted in the Department of Radiotherapy, IPGME&R and SSKM Hospital, Kolkata, India, between February 2020 and November 2022. Sixty patients with biopsy-proven stage III-IVB LA-HNSCC were randomized to receive either two cycles of induction TPF chemotherapy (Arm A) or oral metronomic chemotherapy comprising weekly methotrexate and twice-daily celecoxib (Arm B) while awaiting definitive radiotherapy. Tumour response, treatment-related toxicities, disease-free survival (DFS), overall survival (OS), and quality of life were assessed. Survival outcomes were estimated using the Kaplan-Meier method.
Results: Baseline demographic and clinicopathological characteristics were comparable between the two treatment groups. Induction TPF chemotherapy achieved significantly higher objective tumour response before radiotherapy and superior complete response rates following treatment compared with OMCT. Disease-free survival was significantly longer in the TPF arm, whereas overall survival was comparable between the two groups during the study period.
Conclusions: Induction TPF chemotherapy provided superior tumour response and disease-free survival compared with oral metronomic chemotherapy.
References
Sun H, Yu M, An Z. Global burden of head and neck cancer: Epidemiological transitions, inequities, and projections to 2050. Front Oncol. 2025;15:1665019.
National Centre for Disease Informatics and Research. Report of National Cancer Registry Programme 2020: Incidence, Distribution, Trends in Incidence Rates and Projections of Burden of Cancer (2020-2025). Bengaluru: Indian Council of Medical Research; 2020.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide. CA Cancer J Clin. 2026;76(4):e70090.
Pignon JP, le Maître A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4-14.
Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-9.
Murphy CT, Galloway TJ, Handorf EA, Wang LS, Mehra R, Flieder DB, et al. Survival impact of increasing time to treatment initiation for patients with head and neck cancer. J Clin Oncol. 2016;34(2):169-78.
Chen Z, King W, Pearcey R, Kerba M, Mackillop WJ. The relationship between waiting time for radiotherapy and clinical outcomes: A systematic review of the literature. Radiother Oncol. 2008;87(1):3-16.
Vermorken JB, Remenar E, Van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695-704.
Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357(17):1705-15.
Kerbel RS, Kamen BA. The antiangiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4(6):423-36.
Hanahan D, Bergers G, Bergsland E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105(8):1045-7.
Patil VM, Noronha V, Joshi A, Muddu VK, Dhumal S, Bhosale B, et al. A randomized phase III trial comparing oral metronomic therapy with intravenous cisplatin in patients with recurrent, metastatic and inoperable squamous cell carcinoma of the head and neck. J Clin Oncol. 2015;33(15):6002.
Shenoy VPPK, Manuprasad A, Babu S, Kuriakose MA. Oral metronomic chemotherapy as a feasible preoperative therapy in advanced resectable oral cavity squamous cell carcinomas: A preliminary experience. Ecancermedicalscience. 2022;16:1425.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. Bethesda (MD): U.S. Department of Health and Human Services; 2017.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-76.
Bjordal K, Hammerlid E, Ahlner-Elmqvist M, de Graeff A, Boysen M, Evensen JF, et al. Quality of life in head and neck cancer patients: Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. Eur J Cancer. 1999;35(6):879-85.
Marur S, Forastiere AA. Head and neck squamous cell carcinoma: Update on epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2016;91(3):386-96.
Chow LQM. Head and neck cancer. N Engl J Med. 2020;382(1):60-72.
Hanahan D. Hallmarks of cancer: New dimensions. Cancer Discov. 2022;12(1):31-46.
Pai PS, Vaidya AD, Ghosh-Laskar S. Oral metronomic chemotherapy in recurrent and locally advanced head and neck cancers: An Indian experience. Indian J Cancer. 2013;50(1):58-65.
Joshi A, Patil VM, Noronha V. Oral metronomic chemotherapy in recurrent and metastatic head and neck squamous cell carcinoma: Long-term outcomes from a tertiary cancer centre. South Asian J Cancer. 2017;6(4):180-3.
Hsieh MY, Wang HM, Kang CJ. Metronomic chemotherapy in head and neck squamous cell carcinoma: A systematic review. Oral Oncol. 2023;141:106382.
Coca-Pelaz A, Takes RP, Hutcheson K. Current evidence on treatment delay and induction chemotherapy in locally advanced head and neck squamous cell carcinoma: A contemporary review. Oral Oncol. 2023;138:106306.
Basu A, Ghosh D, Mandal B, Mukherjee P, Maji A. Barriers and explanatory mechanisms in diagnostic delay in four cancers - A health-care disparity? South Asian J Cancer 2019;8:221-5.
Downloads
Published
How to Cite
Issue
Section
